DOTA-PEG-DBCO is a functional group widely used in drug research and development. This classification refers to a specific combination of three functional groups, including DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), PEG (polyethylene glycol), and DBCO (dibenzocyclooctyne). The combination of these functional groups offers several advantages, including improved solubility, stability, and targeting capabilities. In drug research and development, DOTA-PEG-DBCO is commonly used to enhance the specificity and efficacy of therapeutic molecules, including antibodies and peptides, by facilitating their conjugation to imaging agents or other drugs. The unique properties of DOTA-PEG-DBCO make it a valuable tool in the development of targeted therapies for a wide range of diseases, including cancer, cardiovascular disease, and neurological disorders.